Abbott, Syngene to open first R&D nutrition center in India

A leading healthcare company and CRO in India are collaborating to make the country's first nutritional R&D center. The Abbott Nutrition R&D Center is an effort between Abbott Laboratories ($ABT) and Syngene to develop nutritional products while expanding Abbott's nutrition portfolio at the same time.

Syngene will provide a science-based research and innovation team that will work closely with Abbott researchers in the endeavor. Once completed next month, the Bangalore facility will house 50 scientists and researchers.

Focusing on nutritional products will be sure to make an impact on India, where an estimated 50% of its population (think 570 million people) fail to consume adequate nutrients in their daily diets. In addition, India is facing a rising problem with diabetes, a disease 51 million individuals there live with, giving it the world's largest diabetic population.

"With malnutrition and common chronic diseases at their highest in this region, Abbott and Syngene have a common vision and commitment to support the development of a healthier India," remarked Kiran Mazumdar-Shaw, founder, chairwoman and managing director of the Biocon Group, of which Syngene is a subsidiary. "The combined market insights and nutrition science expertise of our two organizations will enable us to address these immediate needs by developing critically important, innovative-yet-affordable nutrition products for the Indian population."

- read the release
- find out more from Reuters

Special Report: Kiran Mazumdar-Shaw - The 25 most influential people in biopharma today

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.